Sentence: Phase 3 data support the use of sunitinib , bevacizumab plus interferon-α and pazopanib for patients with low and intermediate risk of clear-cell renal cell carcinoma .
Drug combination annotation:
[{'class': 'POS', 'spans': ['sunitinib', 'bevacizumab', 'pazopanib', 'interferon-α'], 'is_context_needed': True}]